
LINK . SPRINGER . COM {
}
Title:
Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial | Cancer Chemotherapy and Pharmacology
Description:
Purpose: The purpose of this trial was to evaluate tumor cytoreduction by all-trans retinoic acid (ATRA) in patients with metastatic breast cancer and to characterize the initial pharmacokinetics of this agent. Methods: The study was a single institution, phase II study. The treatment regimen consisted of ATRA administered orally at a dose of 50 mg/m2 three times a day for 14 consecutive days of a 21-day cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient withdrawal. Plasma samples were obtained following the first dose of ATRA for pharmacokinetic analysis. Results: A total of 17 patients with metastatic breast cancer were enrolled in the study, and 14 completed at least one cycle of therapy and were evaluable for response. One patient achieved a partial response in soft tissue of 4 months duration. Three patients had stable disease for 4, 2, and 2 months duration. The remainder had progressive disease. ATRA was reasonably well tolerated. Pharmacokinetic analysis revealed a high degree of interpatient variability in systemic exposure following the initial dose of ATRA. Conclusions: We conclude, that in the dose and schedule tested, ATRA does not have significant activity in patients with hormone-refractory, metastatic breast cancer. Future studies should focus on more intensive investigation of those individuals with very high or low ATRA initial systemic exposure in the hope of expanding our understanding of ATRA
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Health & Fitness
- Education
- Science
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
We can't see how the site brings in money.
Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com has a secret sauce for making money, but we can't detect it yet.
Keywords {🔍}
article, cancer, breast, atra, metastatic, patients, dose, privacy, cookies, content, chemotherapy, pharmacokinetics, phase, access, analysis, information, publish, search, alltrans, retinoic, acid, study, data, log, journal, research, pharmacology, clinical, impact, trial, sutton, warmuth, petros, initial, institution, disease, therapy, open, discover, springer, optional, personal, parties, policy, find, track, cite, linda, marc, william,
Topics {✒️}
phase ii trial month download article/chapter article cancer chemotherapy phase ii study trans retinoic acid metastatic breast cancer privacy choices/manage cookies anthracycline dose reduction related subjects full article pdf european economic area evaluate tumor cytoreduction conditions privacy policy treatment regimen consisted initial pharmacokinetics accepting optional cookies pharmacokinetic analysis revealed chemotherapy delays atra administered orally check access instant access journal finder publish systemic exposure article log article cite privacy policy personal data article sutton books a pharmacokinetics therapy optional cookies pharmacokinetic analysis information manage preferences medical oncology subscription content similar content initial dose institution subscribe data protection essential cookies usage analysis cookies skip meta-analysis adjuvant treatment journal publish pharmacology aims clinical pharmacology social media
Schema {🗺️}
WebPage:
mainEntity:
headline:Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial
description:
Purpose: The purpose of this trial was to evaluate tumor cytoreduction by all-trans retinoic acid (ATRA) in patients with metastatic breast cancer and to characterize the initial pharmacokinetics of this agent. Methods: The study was a single institution, phase II study. The treatment regimen consisted of ATRA administered orally at a dose of 50 mg/m2 three times a day for 14 consecutive days of a 21-day cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient withdrawal. Plasma samples were obtained following the first dose of ATRA for pharmacokinetic analysis. Results: A total of 17 patients with metastatic breast cancer were enrolled in the study, and 14 completed at least one cycle of therapy and were evaluable for response. One patient achieved a partial response in soft tissue of 4 months duration. Three patients had stable disease for 4, 2, and 2 months duration. The remainder had progressive disease. ATRA was reasonably well tolerated. Pharmacokinetic analysis revealed a high degree of interpatient variability in systemic exposure following the initial dose of ATRA. Conclusions: We conclude, that in the dose and schedule tested, ATRA does not have significant activity in patients with hormone-refractory, metastatic breast cancer. Future studies should focus on more intensive investigation of those individuals with very high or low ATRA initial systemic exposure in the hope of expanding our understanding of ATRA's clinical pharmacology, ultimately leading to improved efficacy.
datePublished:
dateModified:
pageStart:335
pageEnd:341
sameAs:https://doi.org/10.1007/s002800050666
keywords:
Key words Retinoids
All-trans retinoic acid Pharmacokinetics
Breast neoplasms
Oncology
Pharmacology/Toxicology
Cancer Research
image:
isPartOf:
name:Cancer Chemotherapy and Pharmacology
issn:
1432-0843
0344-5704
volumeNumber:40
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Linda M. Sutton
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
type:Person
name:Marc A. Warmuth
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
type:Person
name:William P. Petros
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
type:Person
name:Eric P. Winer
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial
description:
Purpose: The purpose of this trial was to evaluate tumor cytoreduction by all-trans retinoic acid (ATRA) in patients with metastatic breast cancer and to characterize the initial pharmacokinetics of this agent. Methods: The study was a single institution, phase II study. The treatment regimen consisted of ATRA administered orally at a dose of 50 mg/m2 three times a day for 14 consecutive days of a 21-day cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient withdrawal. Plasma samples were obtained following the first dose of ATRA for pharmacokinetic analysis. Results: A total of 17 patients with metastatic breast cancer were enrolled in the study, and 14 completed at least one cycle of therapy and were evaluable for response. One patient achieved a partial response in soft tissue of 4 months duration. Three patients had stable disease for 4, 2, and 2 months duration. The remainder had progressive disease. ATRA was reasonably well tolerated. Pharmacokinetic analysis revealed a high degree of interpatient variability in systemic exposure following the initial dose of ATRA. Conclusions: We conclude, that in the dose and schedule tested, ATRA does not have significant activity in patients with hormone-refractory, metastatic breast cancer. Future studies should focus on more intensive investigation of those individuals with very high or low ATRA initial systemic exposure in the hope of expanding our understanding of ATRA's clinical pharmacology, ultimately leading to improved efficacy.
datePublished:
dateModified:
pageStart:335
pageEnd:341
sameAs:https://doi.org/10.1007/s002800050666
keywords:
Key words Retinoids
All-trans retinoic acid Pharmacokinetics
Breast neoplasms
Oncology
Pharmacology/Toxicology
Cancer Research
image:
isPartOf:
name:Cancer Chemotherapy and Pharmacology
issn:
1432-0843
0344-5704
volumeNumber:40
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Linda M. Sutton
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
type:Person
name:Marc A. Warmuth
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
type:Person
name:William P. Petros
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
type:Person
name:Eric P. Winer
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Cancer Chemotherapy and Pharmacology
issn:
1432-0843
0344-5704
volumeNumber:40
Organization:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Linda M. Sutton
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
name:Marc A. Warmuth
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
name:William P. Petros
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
name:Eric P. Winer
affiliation:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
address:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
type:PostalAddress
type:Organization
PostalAddress:
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(31)
- How much revenue does https://www.springernature.com/gp/authors produce monthly?
- What's the income generated by https://link.springernature.com/home/ each month?
- What's the financial outcome of https://order.springer.com/public/cart?
- How much cash flow does https://submission.springernature.com/new-submission/280/3 have monthly?
- Explore the financials of https://www.springernature.com/gp/librarians/licensing/agc/journals
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Linda%20M.%20Sutton income
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Linda%20M.%20Sutton%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Marc%20A.%20Warmuth make?
- What are the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Marc%20A.%20Warmuth%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=William%20P.%20Petros generate?
- What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22William%20P.%20Petros%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Eric%20P.%20Winer?
- Revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Eric%20P.%20Winer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much profit does https://s100.copyright.com/AppDispatchServlet?title=Pharmacokinetics%20and%20clinical%20impact%20of%20all-trans%20retinoic%20acid%20in%20metastatic%20breast%20cancer%3A%20a%20phase%20II%20trial&author=Linda%20M.%20Sutton%20et%20al&contentID=10.1007%2Fs002800050666©right=Springer-Verlag%20Berlin%20Heidelberg&publication=0344-5704&publicationDate=1997-06&publisherName=SpringerNature&orderBeanReset=true make?
- What's the monthly income of https://citation-needed.springer.com/v2/references/10.1007/s002800050666?format=refman&flavour=citation?
- How much does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral pull in?
- How much does https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research bring in each month?
- What's the income generated by https://www.springernature.com/gp/products each month?
- How much does https://www.springernature.com/gp/librarians rake in every month?
- How much does https://www.springernature.com/gp/societies pull in?
- How much does https://www.springernature.com/gp/partners pull in?
- What is the monthly revenue of https://www.springer.com/?
- How much money does https://www.nature.com/ generate?
- Learn about the earnings of https://www.biomedcentral.com/
- How much does https://www.palgrave.com/ rake in every month?
- How much does https://www.apress.com/ bring in each month?
- How much profit is https://www.springernature.com/gp/legal/ccpa making per month?
- https://www.springernature.com/gp/info/accessibility's financial summary
- How much income is https://support.springernature.com/en/support/home earning monthly?
- https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations's financial summary
- What's the monthly money flow for https://www.springernature.com/?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref